Preliminary evidence of active efficacy was observed in this study, particularly among cervical cancer patients, irrespective of PD-L1 expression status, suggesting potential clinical benefits for a broader patient population, including those with negative PD-L1 expression. This evidence concerns the gene CD274 and cervical carcinoma.